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Summary
 
Viral infection often activates the interferon (IFN)-
 
g
 
–inducible gene, 
 
nitric oxide synthase 2
 
(
 
NOS2
 
). Expression of 
 
NOS2
 
 can limit viral growth but may also suppress the immune system
 
and damage tissue. This study assessed each of these effects in genetically deficient NOS2
 
2
 
/
 
2
 
mice after infection with influenza A, a virus against which IFN-
 
g
 
 has no known activity. At
inocula sufficient to cause consolidating pneumonitis and death in wild-type control mice,
NOS2
 
2
 
/
 
2
 
 hosts survived with little histopathologic evidence of pneumonitis. Moreover, they
cleared influenza A virus from their lungs by an IFN-
 
g
 
–dependent mechanism that was not ev-
ident in wild-type mice. Even when the IFN-
 
g
 
–mediated antiviral activity was blocked in
NOS2
 
2
 
/
 
2
 
 mice with anti–IFN-
 
g
 
 mAb, such mice failed to succumb to disease. Further evi-
dence that this protection was independent of viral load was provided by treating NOS2
 
1
 
/
 
1
 
mice with the NOS inhibitor, 
 
N
 
v
 
-methyl-
 
l
 
-arginine (
 
l
 
-NMA). 
 
l
 
-NMA prevented mortality
without affecting viral growth. Thus, host NOS2 seems to contribute more significantly to the
development of influenza pneumonitis in mice than the cytopathic effects of viral replication.
Although NOS2 mediates some antiviral effects of IFN-
 
g
 
, during influenza infection it can
suppress another IFN-
 
g
 
–dependent antiviral mechanism. This mechanism was observed only
in the complete absence of NOS2 activity and appeared sufficient to control influenza A virus
growth in the absence of changes in cytotoxic T lymphocyte activity.
Key words: nitric oxide synthase • interferon 
 
g
 
 • virus infection • inﬂuenza A • cytotoxic T 
lymphocyte
 
T
 
he discovery that the IFN-
 
g
 
–inducible 
 
nitric oxide syn-
thase 2
 
 (
 
NOS2
 
) gene could confer potent antiviral ac-
tivity (1, 2) substantially extended its role as a critical com-
ponent of the innate immune system (3). Yet although a
number of viruses are susceptible to the nitric oxide (NO)-
derived products of NOS2, not all are inhibited (3, 4, and
references therein). Moreover, as a broadly reactive, cell-
permeant radical, NO has the potential to injure uninfected
cells near those harboring virus (3–7, and references
therein). For this reason, NOS2 has also been implicated in
the pathology associated with several viral models (4, 5).
That most of the studies mentioned above have relied on
the use of NOS inhibitors of limited isoform specificity
complicates interpretation of disparate results, since all three
NOS isoforms can exhibit antiviral activity, and at least two
of them (NOS2 and NOS1) can damage cells (3, 4, 8, 9).
We have resorted to 
 
NOS2
 
 gene–targeted mice (10) in
an effort to assess the contribution made by this locus to-
wards pathogenesis and immunoregulation during viral in-
fection. Such mice have confirmed NOS2’s ability to pro-
tect the host during infection by Coxsackie B3 (11) and
ectromelia viruses (11a). Here we studied infection by
pneumotropic influenza A virus for two reasons. First, an
earlier report with pharmacologic inhibitors implicated
NOS2 in host pathology during influenza pneumonitis (6).
Second, although IFN-
 
g
 
 has well-characterized antiviral
activity and is important for NOS2 induction in vivo (1–4),
control of influenza A virus does not seem to require IFN-
 
g
 
,
as evidenced by studies using anti–IFN-
 
g
 
 antibodies (12,
and G. Karupiah, unpublished observations) and IFN-
 
g
 
2
 
/
 
2
 
mice (13, and G. Karupiah, unpublished observations). Sur-
prisingly, treatment with neutralizing antibody revealed that
IFN-
 
g
 
 can control influenza A virus, but only when NOS2
is absent.
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Materials and Methods
 
Mice.
 
NOS2
 
2
 
/
 
2
 
 
 
mice were generated as described (10).
NOS2
 
2
 
/
 
2
 
 and NOS2
 
1
 
/
 
1
 
 littermates (129/SvEv 
 
3 
 
C57BL/6 F
 
2
 
)
were bred at the specific pathogen–free unit, John Curtin School
of Medical Research. NOS2 genotype was confirmed by PCR
(14). Experiments were performed according to institutional
guidelines for animal care and use.
 
Virus Infection and Enumeration.
 
Influenza A virus (strain A/
PR/8/34) was directly instilled in 30 
 
m
 
l PBS into the nasal cavity
under Avertin (1.5 ml/100 g) anesthesia, and titers were thereaf-
ter determined via serial dilutions of lung homogenates plated
onto MDCK cell monolayers for detection of PFU (15). The
limit of assay detection was 2.0 log
 
10
 
 PFU.
 
Lung Immunocyte Isolation.
 
Leukocytes were isolated as out-
lined (12) from HBSS-perfused and aseptically excised lungs from
groups of influenza virus–infected mice (
 
n
 
 
 
5 
 
5 per group). Popu-
lations consisted of 
 
z
 
40–50% T lymphocytes (CD3
 
1
 
), 20–30% B
lymphocytes (CD45R/B220
 
1
 
), and 10–12% macrophages (F4/
80
 
1
 
) as determined by flow cytometry.
 
Bronchoalveolar Lavage Fluid NO
 
x
 
 Assay.
 
Bronchoalveolar la-
vage fluid (BALF) consisted of washings from intratracheal instil-
lation of 1.0 ml PBS. Nitrite was measured by a diazotization as-
say (14) with a sensitivity of 4 
 
m
 
M after NO
 
3
 
2
 
 
 
was converted to
NO
 
2
 
2
 
 via nitrate reductase.
 
Cytotoxicity Assays.
 
Influenza A virus–infected and uninfected
EL-4 lymphoma cells were used as targets for measurement of anti-
influenza A virus–specific, class I MHC–restricted CTL activity of
lung parenchymal cells using standard 
 
51
 
Cr-release assays (16, 17).
 
IFN-
 
g
 
 ELISA Analysis.
 
A sandwich ELISA (18) was used to
measure IFN-
 
g
 
 levels in BALF and from culture supernatants of
lung immunocytes (5 
 
3 
 
10
 
6
 
; 
 
z
 
50% CD3
 
1
 
) of influenza A/PR/
8/34 virus–infected mice coincubated for 48 h with influenza
virus–infected, mitomycin C–treated (50 
 
m
 
g/ml) genotype-
matched lung parenchymal cells (5 
 
3 
 
10
 
5
 
). Recombinant MuIFN-
 
g
 
(Genzyme Corp., Cambridge, MA) served as the standard, with
an assay detection limit of 3 U/ml. Con A was added at 4 
 
m
 
g/ml
(Sigma Chemical Co., St. Louis, MO).
 
Histology.
 
Formalin-fixed, paraffin-embedded tissues were
sectioned (5 
 
m
 
m) and stained with hematoxylin and eosin as out-
lined (18).
 
Neutralization of NOS2 and IFN-
 
g
 
 In Vivo. N
 
v
 
-methyl-
 
l
 
-argi-
nine (
 
l
 
-NMA; Sigma Chemical Co.) or its inactive 
 
d
 
-enantiomer
(
 
d
 
-NMA) was administered via daily intraperitoneal injection,
and efficacy was verified by BALF nitrite plus nitrate (NO
 
x
 
) assay.
Neutralization of IFN-
 
g
 
 was achieved by injection of 1 mg i.p.
anti–MuIFN-
 
g
 
 mAb (clone XMG-6, rat IgG
 
1
 
 [17, 18]) in 200 
 
m
 
l
PBS on days 0, 2, and 4 after infection. Control animals received
an isotype-matched mAb against bacterial 
 
b
 
-galactosidase (clone
GL 113, rat IgG
 
1
 
).
 
Statistical Analysis.
 
Unpaired Student’s 
 
t
 
 tests at 95% confi-
dence levels were performed using InStat software, Version 2.00
(GraphPad Software for Science, San Diego, CA).
 
Results and Discussion
 
Augmented Virus Clearance and Enhanced Survival of
NOS2
 
2
 
/
 
2
 
 
 
Mice Infected with Influenza A Virus.
 
In previous
work, mice treated with anti–IFN-
 
g
 
 antibodies (12, and G.
Karupiah, unpublished observations) or lacking IFN-
 
g
 
 (13,
and G. Karupiah, unpublished observations) responded to
influenza A virus similarly to control mice, even though
 
their capacity for NOS2 expression is known to be im-
paired (19, 20). Our findings in NOS2
 
2
 
/
 
2
 
 mice not only
corroborated the implication that NOS2 is dispensable for
the control of influenza A virus in the lower respiratory
tract, but also demonstrated that NOS2 is detrimental in
this setting. Thus, intranasal inoculation with the virulent
A/PR/8/34 strain led to rapid pneumonitis and early mor-
tality in wild-type mice given 300, 400, or 500 hemagglu-
tinin units (HAU) of virus. In contrast, NOS2
 
2
 
/
 
2
 
 mice
started to succumb only at 600 HAU (Fig. 1 
 
a).
Influenza A virus titers in the lungs of d-NMA–treated
controls given 400 HAU of virus reached 5.6 6 0.2 log10
PFU by day 6 after infection, whereas in NOS22/2 mice
lung virus titers were below the limit of detection (,2.0
log10 PFU; Fig. 1 b). Surprisingly, l-NMA–treated wild-
type mice harbored viral loads similar to their d-NMA–
treated littermates (Fig. 1 b) but, unlike the latter, they
showed no signs of morbidity and survived through the 21-d
period of observation (data not shown). This outcome
suggested (a) that NOS22/2 mice selectively expressed a
potent antiinfluenza effector mechanism, and (b) the high
output NO pathway may contribute to pathogenesis, since
both l-NMA– and d-NMA–treated wild-type mice failed
to eradicate the virus but only those given the inactive
d-enantiomer proved susceptible, dying between days 7
and 8 after infection, like their untreated counterparts (Fig.
1 a, and data not shown).
An IFN-g–dependent Pathway Restricts Influenza Virus Repli-
cation in NOS22/2 Mice. Experiments in b2-microglobulin2/2
mice (21) and Fas2/2 3 perforin2/2 chimeras (22) demon-
Figure 1. Disruption of NOS2 confers a protective effect during influ-
enza A virus infection. (a) Mortality in male NOS21/1 or NOS22/2 mice
(n 5 20 per group at each dose) inoculated intranasally with 300, 400,
500, or 600 HAU influenza A (strain A/PR/8/34) and monitored for 21 d.
Data represent four independent experiments. (b) Lung influenza A titers
in d-NMA– or l-NMA–treated NOS21/1 mice and NOS22/2 mice in-
tranasally infected with 400 HAU of virus and determined at day 6 after
infection. Dashed line, Assay detection limit. Data are derived from three
experiments and expressed as log10 virus titers/gram tissue 6 SEM. *P ,
0.01 versus NOS22/2 group, unpaired t test.1543 Karupiah et al. Brief Definitive Report
strated the importance of CD81 T lymphocytes for elimi-
nation of influenza A virus from the lung. To determine if
this effector arm of the immune response contributed to
rapid virus clearance in the NOS22/2 host, we examined
influenza-specific CTL activity on day 6 after infection.
Lung immunocytes lysed the influenza virus–infected tar-
gets equally well irrespective of NOS2 status (Fig. 2 a).
However, measurement of local IFN-g production by
these cells (Fig. 2 b) and in BALF (Fig. 2 c) revealed that
NOS22/2 mice exhibited 1.9–3.4-fold higher levels of
IFN-g than wild-type hosts; this increase was independent
of antigen load (Fig. 1 b).
Whether such an increase in IFN-g secretion could ac-
count for the reduced viral burden in mutant animals was
assessed by intraperitoneal injection with mAb to IFN-g
(18). Assay of virus infectivity levels 6 d after infection
demonstrated that IFN-g–dependent anti-influenza A virus
mechanisms were operative in mutant mice as depicted by
the high titers comparable to those of l-NMA or d-NMA–
treated wild-type controls (Fig. 2 d). In contrast, NOS22/2
animals receiving an IgG1 isotype-matched control mAb
still retained their capacity to restrict influenza virus repli-
cation within the lungs; titers were below the level of de-
tection (Fig. 2 d).
Elevated NO Production Is Associated with Pulmonary Pa-
thology in Influenza Virus–infected Wild-type Hosts. The de-
mise of untreated or d-NMA–treated NOS21/1 mice was
not due to uncontrolled viral growth, since l-NMA–
treated wild-type or anti–IFN-g–treated NOS22/2 hosts
also displayed overwhelming lung viral burdens yet showed
no signs of morbidity throughout the 3-wk experimental
period (Figs. 1 b, 2 d, and data not shown). Survival of the
latter two groups implied that pulmonary injury in d-NMA–
treated animals arose as a consequence of excessive NO
production rather than by direct viral cytopathic effects.
Indeed, NOx levels within the BALF of d-NMA–treated
NOS21/1 mice rose appreciably (z3.4–4.0-fold) during
the course of infection (Fig. 3 a), whereas this increase was
absent in mutant mice and inhibited by 77–90% in l-NMA–
treated controls (Fig. 3 a). Histopathologic examination
revealed massive inflammatory foci and edema within the
lungs of all d-NMA–treated wild-type mice as part of the
consolidating pneumonitis observed 6 d after infection
(Fig. 3 b). Neutrophils and alveolar macrophages were
especially prominent. Both are capable of releasing cyto-
toxic oxidants besides NO (6, 23), such as the superoxide
anion (O2
2), which can react with the latter to yield
more  damaging products like peroxynitrite (ONOO2 [3]).
Akaike et al. have demonstrated the local formation of both
ONOO2 and NO-hemoglobin in murine influenza infec-
tion using nitrotyrosine footprinting and electron spin reso-
nance spectroscopy (6), while NO-thiol adducts also ap-
pear elevated in wild-type but not NOS22/2 mice during
tuberculosis (14). Thus, it is conceivable that several NO-
derived species acted in concert to cause influenza-associ-
ated pathology.
Absence of Consolidating Pneumonitis in NOS22/2 Mice.
In marked contrast to the severe pneumonitis seen for all
d-NMA–treated NOS21/1 mice, the majority of mutant
animals (z70%) lacked evidence of pathology. A mild de-
gree of inflammation was observed in the remainder; an
example of the latter is depicted in Fig. 3 b. These results
are consistent with the idea that NOS2 promotes the de-
velopment of viral pneumonia. Additional support for
this concept comes from recent studies using NOS in-
hibitors during infection with HSV-1 (7), murine CMV
(24), or the influenza A/Kumamoto/Y5/67 (H2N2) mouse
Figure 2. IFN-g–dependent antiinfluenza virus activity in NOS22/2
mice is not accompanied by changes in CTL response. (a) Ex vivo CTL
activity of lung parenchymal cells (day 6 after infection) from d-NMA–
or l-NMA–treated NOS21/1 mice and NOS22/2 mice intranasally in-
fected with 400 HAU of virus. Shown are group means (n 5 4 for each of
two independent experiments); SEMs fall within the symbols. (b) IFN-g
production by explanted lung parenchymal cells from influenza A virus–
infected NOS21/1 and NOS22/2 mice cultured in vitro with uninfected
lung immunocytes, influenza-infected stimulators, or Con A for 48 h.
Data are presented as means of triplicate cultures 6 SEM (from pooled
lung immunocytes of five mice per group, and represent two independent
experiments). (c) IFN-g levels in the BALF of d-NMA– or l-NMA–
treated NOS21/1 mice and NOS22/2 mice intranasally infected with 400
HAU of virus determined at day 6 after infection. Individual samples
were assayed in triplicate; horizontal bars, group means. *P , 0.01 versus
d-NMA–treated group, unpaired t test. (d) Influenza A virus titers in the
lungs of NOS22/2 mice treated with anti–MuIFN-g (n 5 14) or control
IgG1 mAb (n 5 14); or in NOS21/1 mice given d-NMA (n 5 10) or
l-NMA (n 5 14). Untreated NOS21/1 mice (UT) served as drug-free
controls (n 5 4). Dashed line, Assay detection limit. Data shown represent
three experiments and are expressed as log10 virus titers/gram tissue 6
SEM. *P , 0.01 versus control IgG1 mAb–treated group, unpaired t test.1544 Influenza Infection in NOS2 Gene–targeted Mice
adapted strain (6). Inhibition of NOS fully protected mice
from HSV-1–dependent lung injury despite a 17-fold in-
crease in viral titers (7). That NO was necessary to control
HSV-1 in vivo substantiated earlier experiments in vitro (1,
2). In contrast, in the present work, the functional loss of
NOS2 alleviated pneumonitis and greatly improved sur-
vival irrespective of whether influenza virus was cleared
(NOS22/2 hosts) or not (NOS21/1 mice given l-NMA).
Reduced pathology has also recently been noted in NOS22/2
mice infected with Mycobacterium avium (25) and Toxoplasma
gondii (26).
IFN-g has been implicated as the major cytokine re-
sponsible for NOS2 induction during influenza A–induced
pneumonitis (6). Aside from IFN-g’s purported proinflam-
matory action in wild-type mice, we found that heightened
IFN-g release was both associated with and required for in-
fluenza A virus clearance in NOS22/2 animals, an effect
unaccompanied by changes in antiviral CTL activity (Fig. 2,
a–d). The effect was specific for mutant mice, since l-NMA–
treated wild-type mice had comparable IFN-g levels but
failed to limit viral growth. IFN-g thus appears to cooper-
ate with immune components otherwise subject to sup-
pression by NOS2 and not by NOS1 and/or NOS3. Com-
plete inhibition of NOS2 by disruption of the gene
encoding it, rather than the partial inhibition afforded by
treatment of NOS21/1 mice with l-NMA, also appeared
necessary to permit expression of the IFN-g–dependent
antiinfluenza mechanism. Among pertinent candidates for
components of this mechanism are MHC class II expres-
sion by pulmonary dendritic cells (27) and Th1 cell prolif-
eration plus cytokine production (28, 29). Each could be
compromised by NOS2, which can limit T cell responsive-
ness to IL-2 in the lungs of rats and mice (28) as well as in-
hibit the release of IL-12 and elevate the expression of
TGF-b as shown in Leishmania major–infected NOS22/2
mice (30). In this manner, the high output NO pathway
may regulate IFN-g secretion via a feedback mechanism,
such that once infection is cleared, autotoxic NO produc-
tion is extinguished.
Beyond this, how NOS2 might influence the underlying
molecular events leading to cytokine gene expression and
action during antiviral immunity remains speculative. NO
can activate or disable protein tyrosine kinases of the Janus
kinase (JAK), extracellular signal–regulatory kinase (ERK),
and src families, as well as the transcription factor nuclear
factor (NF)-kB, and thus may affect cytokine signaling (31,
and references therein). Indeed, NOS22/2 animals have al-
tered levels of NF-kB and signal transducer and activator of
transcription (STAT)3 activation in hemorrhage/resuscita-
tion (32) and perturbed IFN-g release in L. major (28, 29)
and influenza A infections (Fig 2, b and c). Cytokine ex-
pression could also be regulated by NOS2 at the posttrans-
Figure 3. Absence of inducible NO production and consolidating pneumonitis in the lungs of infected NOS22/2 mice. (a) NO2
2 1 NO3
2 (NOx) lev-
els in the BALF of d-NMA– or l-NMA–treated NOS21/1 mice and NOS22/2 mice intranasally infected with 400 HAU of virus determined at day 6 af-
ter infection. Individual samples were assayed in triplicate after conversion to NO2
2; horizontal bars, group means. (b, top) Histological analyses of lungs
from uninfected NOS21/1 and NOS22/2 hosts; original magnification: 3250. (Bottom) Consolidating pneumonitis in NOS21/1 mice which was absent
in NOS22/2 mutant animals at day 6 after infection; original magnification: 3250. At least nine mice per group were examined.1545 Karupiah et al. Brief Definitive Report
lational level. For example, S-nitrosylation of the active site
cysteine residue in caspases leads to their inactivation (33).
If this inhibition were to be relieved in NOS22/2 mice, ab-
normally active caspase-1 might more readily promote the
release of IL-18 (34, 35), a powerful inducer of IFN-g.
During infection, NOS2 probably displays all three of its
major effects to variable degrees—antimicrobial, inflamma-
tory, and immunosuppressive. The results seen here with
influenza A virus–infected mice appear to illustrate one ex-
treme, in which the latter two effects dominate.
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